Masahiro Tsuboi, MD, a surgeon at the National Cancer Center Hospital East in Japan, discusses the updated survival results of the phase 3 ADAURA trial (NCT02511106) in resectable EGFR-mutant non–small cell lung cancer. 

Lung Cancer

JAN-22-OSD1275 - /clinical/lung-cancer

The OncLive Lung Cancer condition center page is a comprehensive resource for clinical news and expert insights on non–small cell lung cancer, small cell lung cancer, mesothelioma, and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in lung cancer.

Publications

® Publications page showcases all of the exclusive content that appears in the twice-monthly print publication 

 Multiple print supplements that run in tandem with 

, including meeting reporters, priority reports, My Treatment Approach, and Year in Review publications, can all be found on this Publications page. 

OncLive TV

® TV is an editorial video program featuring one-on-one live and/or virtual interviews with key opinion leaders in the oncology field for their expert insight on breaking news, regulatory updates, practice-changing data presented at medical meetings, and other pivotal topics in a cancer specialty, including breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, gynecologic cancers, and hematologic cancers. 

The Evolving Treatment Paradigm for Stage I-IIIB NSCLC

Scientific Interchange & Workshop

Masahiro Tsuboi, MD, discusses the updated survival results of the phase 3 ADAURA trial in resectable EGFR-mutant non–small cell lung cancer. 

Dr Tsuboi on Updated Survival Results of the ADAURA Trial in Resectable NSCLC